The Predictive Value of PD-L1 Expression Level in Evaluating the Cost-Effectiveness of Atezolizumab/Pembrolizumab

OBJECTIVE: Recently, the significant improvement of atezolizumab and pembrolizumab over chemotherapy for treatment-naïve stage IV non-small cell lung cancer (NSCLC) has been demonstrated, but the cost-effectiveness of these regimens remains unknown. METHODS: A Markov model was adapted from the US he...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Shen, Li, Yiyuan, Gu, Dian, Luo, Shaohong, Huang, Xiaoting, Dong, Liangliang, Xu, Xiongwei, Lin, Peili, Weng, Xiuhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076131/
https://www.ncbi.nlm.nih.gov/pubmed/35530317
http://dx.doi.org/10.3389/fonc.2022.857452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9076131/
https://www.ncbi.nlm.nih.gov/pubmed/35530317
http://dx.doi.org/10.3389/fonc.2022.857452

Ejemplares similares